Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-10

AUTHORS

Rahat Noor, Agop Y. Bedikian, Sandy Mahoney, Roland Bassett, Kevin Kim, Nicholas Papadopoulos, Wen-Jen Hwu, Patrick Hwu, Jade Homsi

ABSTRACT

BACKGROUND: Treatment of metastatic melanoma with interleukin-2-based biochemotherapy involves administration of a combination of moderately and highly emetogenic chemotherapies over 5 days. Corticosteroids for the prevention of biochemotherapy-induced nausea and vomiting (CINV) are contraindicated because they cause lysis of LAK cells produced in response to interleukin-2. Palonosetron is a long-acting, highly potent, second-generation serotonin receptor antagonist. The recommended dosing schedule of palonosetron for the control of CINV due to biochemotherapy is not known. METHODS: In a phase II design, treatment-naïve patients with metastatic melanoma undergoing the first cycle of biochemotherapy were randomized to receive palonosetron 0.25 mg intravenously for CINV prophylaxis on either days 1 and 4 (schedule 1) or days 1, 3, and 5 (schedule 2). All patients received dacarbazine on day 1, cisplatin, vinblastine, and interleukin-2 on days 1-4, and interferon alpha-2b on days 1-5. We evaluated and compared, by palonosetron dosing schedule, the pattern and the severity of CINV during the first 7 days of treatment and the duration of the 21-day cycle as well as the impact on daily function with the Functional Living Index-Emesis. RESULTS: Thirty patients (median age 53 years) were enrolled. Eighteen (60%) were men. A consistent trend of a better control of both nausea and vomiting favoring schedule 2 was observed during the first 7 days and throughout the cycle. Significantly more patients experienced nausea on any day during the first 7 days on schedule 1 (mean number of episodes 8.1 ± 1.5) than on schedule 2 (mean number of episodes 5.6 ± 2.3, p = 0.028). The impact on daily function was similar between the two groups. CONCLUSIONS: Both dosing schedules of palonosetron were tolerated well. Alternate day dosing of palonosetron was more effective in controlling CINV in this patient population. More... »

PAGES

2583-2588

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00520-011-1359-6

DOI

http://dx.doi.org/10.1007/s00520-011-1359-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039959170

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22274951


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiemetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interleukin-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoquinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nausea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinuclidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serotonin Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vomiting", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noor", 
        "givenName": "Rahat", 
        "id": "sg:person.0625610040.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625610040.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bedikian", 
        "givenName": "Agop Y.", 
        "id": "sg:person.01354074226.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354074226.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mahoney", 
        "givenName": "Sandy", 
        "id": "sg:person.01047564210.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047564210.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bassett", 
        "givenName": "Roland", 
        "id": "sg:person.01003146511.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003146511.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Kevin", 
        "id": "sg:person.0615126743.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615126743.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papadopoulos", 
        "givenName": "Nicholas", 
        "id": "sg:person.014057560242.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014057560242.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hwu", 
        "givenName": "Wen-Jen", 
        "id": "sg:person.01262760703.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262760703.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hwu", 
        "givenName": "Patrick", 
        "id": "sg:person.0702415721.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702415721.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Homsi", 
        "givenName": "Jade", 
        "id": "sg:person.01045603743.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045603743.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00434947", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006260699", 
          "https://doi.org/10.1007/bf00434947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp584", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007050927"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199754020-00008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009456971", 
          "https://doi.org/10.2165/00003495-199754020-00008"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.11817", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010335838"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.0483", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017094741"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl137", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023612379"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdh047", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026990645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199855020-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030295362", 
          "https://doi.org/10.2165/00003495-199855020-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14656566.1.2.207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030965593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/07357900009038248", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033539371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ddr.430280111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037691728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-003-0482-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038839491", 
          "https://doi.org/10.1007/s00520-003-0482-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/07357900802027073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039879205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0922-4106(90)90190-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041755679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.20073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042069193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a010762", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042885449"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdg417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047729604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.1995.tb13282.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050303878"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.07.044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074487017", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.4-3-191", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074487017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.9.2971", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549933"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.1.158", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074572226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077181555", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2009.0039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077902904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2009.0039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077902904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ndt/9.10.1456", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082400333"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.5.1752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083260950"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10", 
    "datePublishedReg": "2012-10-01", 
    "description": "BACKGROUND: Treatment of metastatic melanoma with interleukin-2-based biochemotherapy involves administration of a combination of moderately and highly emetogenic chemotherapies over 5 days. Corticosteroids for the prevention of biochemotherapy-induced nausea and vomiting (CINV) are contraindicated because they cause lysis of LAK cells produced in response to interleukin-2. Palonosetron is a long-acting, highly potent, second-generation serotonin receptor antagonist. The recommended dosing schedule of palonosetron for the control of CINV due to biochemotherapy is not known.\nMETHODS: In a phase II design, treatment-na\u00efve patients with metastatic melanoma undergoing the first cycle of biochemotherapy were randomized to receive palonosetron 0.25 mg intravenously for CINV prophylaxis on either days 1 and 4 (schedule 1) or days 1, 3, and 5 (schedule 2). All patients received dacarbazine on day 1, cisplatin, vinblastine, and interleukin-2 on days 1-4, and interferon alpha-2b on days 1-5. We evaluated and compared, by palonosetron dosing schedule, the pattern and the severity of CINV during the first 7 days of treatment and the duration of the 21-day cycle as well as the impact on daily function with the Functional Living Index-Emesis.\nRESULTS: Thirty patients (median age 53 years) were enrolled. Eighteen (60%) were men. A consistent trend of a better control of both nausea and vomiting favoring schedule 2 was observed during the first 7 days and throughout the cycle. Significantly more patients experienced nausea on any day during the first 7 days on schedule 1 (mean number of episodes 8.1 \u00b1 1.5) than on schedule 2 (mean number of episodes 5.6 \u00b1 2.3, p = 0.028). The impact on daily function was similar between the two groups.\nCONCLUSIONS: Both dosing schedules of palonosetron were tolerated well. Alternate day dosing of palonosetron was more effective in controlling CINV in this patient population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00520-011-1359-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1103473", 
        "issn": [
          "0941-4355", 
          "1433-7339"
        ], 
        "name": "Supportive Care in Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy", 
    "pagination": "2583-2588", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "be59578d953630c3de3d03af5ac46a6137b32aa010b1c90f35be7c2fbc61352e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22274951"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9302957"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00520-011-1359-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039959170"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00520-011-1359-6", 
      "https://app.dimensions.ai/details/publication/pub.1039959170"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00520-011-1359-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00520-011-1359-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00520-011-1359-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00520-011-1359-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00520-011-1359-6'


 

This table displays all metadata directly associated to this object as RDF triples.

265 TRIPLES      21 PREDICATES      70 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00520-011-1359-6 schema:about N188b2162d7674dea96e03ad212388589
2 N264ebb7fd0634c57a9bdd3e16fdb1584
3 N373ecd5f775b4bf7a4aab3347c2003a8
4 N3ced0851dbde41b796de708de1746cb1
5 N4520a537a187477c83ac9e9e8b217eb5
6 N4652b2011f8c4bbe92a56e38757c77b9
7 N5d6eb478530949f0842f60c854e7e87c
8 N6b0a5ca4e34d4c28b3575c07633eb04f
9 N6ea3fef5d9d642bc92c0b29d0de32143
10 N76fa5be234d54983b057377de2ca266a
11 N9dd4aef1ead64432890433b8331754ac
12 Nc03107432e504c0b9789b069d187d468
13 Ne5b6c543e2844bfe99f015a26633fffe
14 Nf4a3e80356bc4726b74d283a00beb47b
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N986f9e0a1eab4011aea3e7380669dc95
18 schema:citation sg:pub.10.1007/bf00434947
19 sg:pub.10.1007/s00520-003-0482-4
20 sg:pub.10.2165/00003495-199754020-00008
21 sg:pub.10.2165/00003495-199855020-00002
22 https://app.dimensions.ai/details/publication/pub.1074487017
23 https://app.dimensions.ai/details/publication/pub.1077181555
24 https://doi.org/10.1002/cncr.11817
25 https://doi.org/10.1002/ddr.430280111
26 https://doi.org/10.1016/0922-4106(90)90190-9
27 https://doi.org/10.1080/07357900802027073
28 https://doi.org/10.1093/annonc/mdg417
29 https://doi.org/10.1093/annonc/mdh047
30 https://doi.org/10.1093/annonc/mdl137
31 https://doi.org/10.1093/annonc/mdp584
32 https://doi.org/10.1093/ndt/9.10.1456
33 https://doi.org/10.1093/oxfordjournals.annonc.a010762
34 https://doi.org/10.1111/j.1476-5381.1995.tb13282.x
35 https://doi.org/10.1200/jco.1998.16.5.1752
36 https://doi.org/10.1200/jco.1999.17.9.2971
37 https://doi.org/10.1200/jco.2000.18.1.158
38 https://doi.org/10.1200/jco.2002.07.044
39 https://doi.org/10.1200/jco.2006.06.0483
40 https://doi.org/10.1517/14656566.1.2.207
41 https://doi.org/10.1634/theoncologist.4-3-191
42 https://doi.org/10.3109/07357900009038248
43 https://doi.org/10.3322/caac.20073
44 https://doi.org/10.6004/jnccn.2009.0039
45 schema:datePublished 2012-10
46 schema:datePublishedReg 2012-10-01
47 schema:description BACKGROUND: Treatment of metastatic melanoma with interleukin-2-based biochemotherapy involves administration of a combination of moderately and highly emetogenic chemotherapies over 5 days. Corticosteroids for the prevention of biochemotherapy-induced nausea and vomiting (CINV) are contraindicated because they cause lysis of LAK cells produced in response to interleukin-2. Palonosetron is a long-acting, highly potent, second-generation serotonin receptor antagonist. The recommended dosing schedule of palonosetron for the control of CINV due to biochemotherapy is not known. METHODS: In a phase II design, treatment-naïve patients with metastatic melanoma undergoing the first cycle of biochemotherapy were randomized to receive palonosetron 0.25 mg intravenously for CINV prophylaxis on either days 1 and 4 (schedule 1) or days 1, 3, and 5 (schedule 2). All patients received dacarbazine on day 1, cisplatin, vinblastine, and interleukin-2 on days 1-4, and interferon alpha-2b on days 1-5. We evaluated and compared, by palonosetron dosing schedule, the pattern and the severity of CINV during the first 7 days of treatment and the duration of the 21-day cycle as well as the impact on daily function with the Functional Living Index-Emesis. RESULTS: Thirty patients (median age 53 years) were enrolled. Eighteen (60%) were men. A consistent trend of a better control of both nausea and vomiting favoring schedule 2 was observed during the first 7 days and throughout the cycle. Significantly more patients experienced nausea on any day during the first 7 days on schedule 1 (mean number of episodes 8.1 ± 1.5) than on schedule 2 (mean number of episodes 5.6 ± 2.3, p = 0.028). The impact on daily function was similar between the two groups. CONCLUSIONS: Both dosing schedules of palonosetron were tolerated well. Alternate day dosing of palonosetron was more effective in controlling CINV in this patient population.
48 schema:genre research_article
49 schema:inLanguage en
50 schema:isAccessibleForFree false
51 schema:isPartOf Ncfe19268fa7649bb9a020e77914c38b9
52 Nd3a2b8516ff14e5497b8f06d38101d1e
53 sg:journal.1103473
54 schema:name Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy
55 schema:pagination 2583-2588
56 schema:productId N0aded34f1a904b4991147a17757be749
57 N3cde9ca3873a4e419152309712c1ed9d
58 N59361b896aca4dd38992fb4a0780fe11
59 N7aa7f2acbc0847ada3754b3531e68790
60 Nf609022d5ce649029f9ff4e714c5094a
61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039959170
62 https://doi.org/10.1007/s00520-011-1359-6
63 schema:sdDatePublished 2019-04-11T00:16
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher N61173fcad1f345d48d1d67574bd280d2
66 schema:url http://link.springer.com/10.1007%2Fs00520-011-1359-6
67 sgo:license sg:explorer/license/
68 sgo:sdDataset articles
69 rdf:type schema:ScholarlyArticle
70 N0aded34f1a904b4991147a17757be749 schema:name readcube_id
71 schema:value be59578d953630c3de3d03af5ac46a6137b32aa010b1c90f35be7c2fbc61352e
72 rdf:type schema:PropertyValue
73 N1666cbdaf148485ea200a03a825b4a14 rdf:first sg:person.0702415721.17
74 rdf:rest N474cde3b8361477cb31d26f07e20cf98
75 N188b2162d7674dea96e03ad212388589 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Serotonin Antagonists
77 rdf:type schema:DefinedTerm
78 N244b4bf4480d4a51a9e248fd1e8df9c2 rdf:first sg:person.01047564210.46
79 rdf:rest Ndcd0bad6d3a2424f9a0ff0dff6098acb
80 N264ebb7fd0634c57a9bdd3e16fdb1584 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Humans
82 rdf:type schema:DefinedTerm
83 N27c3769381114a6d8440dff9ad99c8b4 rdf:first sg:person.0615126743.56
84 rdf:rest N316c3f39aeeb430db65e73e70d2ab961
85 N316c3f39aeeb430db65e73e70d2ab961 rdf:first sg:person.014057560242.98
86 rdf:rest Na45ac9c00d594cdfaf30b0bc12428dfd
87 N373ecd5f775b4bf7a4aab3347c2003a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Interleukin-2
89 rdf:type schema:DefinedTerm
90 N3cde9ca3873a4e419152309712c1ed9d schema:name dimensions_id
91 schema:value pub.1039959170
92 rdf:type schema:PropertyValue
93 N3ced0851dbde41b796de708de1746cb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Female
95 rdf:type schema:DefinedTerm
96 N4520a537a187477c83ac9e9e8b217eb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Dose-Response Relationship, Drug
98 rdf:type schema:DefinedTerm
99 N4652b2011f8c4bbe92a56e38757c77b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Isoquinolines
101 rdf:type schema:DefinedTerm
102 N474cde3b8361477cb31d26f07e20cf98 rdf:first sg:person.01045603743.37
103 rdf:rest rdf:nil
104 N59361b896aca4dd38992fb4a0780fe11 schema:name pubmed_id
105 schema:value 22274951
106 rdf:type schema:PropertyValue
107 N5d6eb478530949f0842f60c854e7e87c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Male
109 rdf:type schema:DefinedTerm
110 N61173fcad1f345d48d1d67574bd280d2 schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 N6b0a5ca4e34d4c28b3575c07633eb04f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Quinuclidines
114 rdf:type schema:DefinedTerm
115 N6ea3fef5d9d642bc92c0b29d0de32143 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Middle Aged
117 rdf:type schema:DefinedTerm
118 N76fa5be234d54983b057377de2ca266a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Antineoplastic Agents
120 rdf:type schema:DefinedTerm
121 N7aa7f2acbc0847ada3754b3531e68790 schema:name doi
122 schema:value 10.1007/s00520-011-1359-6
123 rdf:type schema:PropertyValue
124 N986f9e0a1eab4011aea3e7380669dc95 rdf:first sg:person.0625610040.61
125 rdf:rest Nffd16825671a4f539ebdb0bf2181b5e5
126 N9dd4aef1ead64432890433b8331754ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Vomiting
128 rdf:type schema:DefinedTerm
129 Na45ac9c00d594cdfaf30b0bc12428dfd rdf:first sg:person.01262760703.36
130 rdf:rest N1666cbdaf148485ea200a03a825b4a14
131 Nc03107432e504c0b9789b069d187d468 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Antiemetics
133 rdf:type schema:DefinedTerm
134 Ncfe19268fa7649bb9a020e77914c38b9 schema:issueNumber 10
135 rdf:type schema:PublicationIssue
136 Nd3a2b8516ff14e5497b8f06d38101d1e schema:volumeNumber 20
137 rdf:type schema:PublicationVolume
138 Ndcd0bad6d3a2424f9a0ff0dff6098acb rdf:first sg:person.01003146511.25
139 rdf:rest N27c3769381114a6d8440dff9ad99c8b4
140 Ne5b6c543e2844bfe99f015a26633fffe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Nausea
142 rdf:type schema:DefinedTerm
143 Nf4a3e80356bc4726b74d283a00beb47b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Melanoma
145 rdf:type schema:DefinedTerm
146 Nf609022d5ce649029f9ff4e714c5094a schema:name nlm_unique_id
147 schema:value 9302957
148 rdf:type schema:PropertyValue
149 Nffd16825671a4f539ebdb0bf2181b5e5 rdf:first sg:person.01354074226.00
150 rdf:rest N244b4bf4480d4a51a9e248fd1e8df9c2
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
155 schema:name Clinical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1103473 schema:issn 0941-4355
158 1433-7339
159 schema:name Supportive Care in Cancer
160 rdf:type schema:Periodical
161 sg:person.01003146511.25 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
162 schema:familyName Bassett
163 schema:givenName Roland
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003146511.25
165 rdf:type schema:Person
166 sg:person.01045603743.37 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
167 schema:familyName Homsi
168 schema:givenName Jade
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045603743.37
170 rdf:type schema:Person
171 sg:person.01047564210.46 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
172 schema:familyName Mahoney
173 schema:givenName Sandy
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047564210.46
175 rdf:type schema:Person
176 sg:person.01262760703.36 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
177 schema:familyName Hwu
178 schema:givenName Wen-Jen
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262760703.36
180 rdf:type schema:Person
181 sg:person.01354074226.00 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
182 schema:familyName Bedikian
183 schema:givenName Agop Y.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354074226.00
185 rdf:type schema:Person
186 sg:person.014057560242.98 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
187 schema:familyName Papadopoulos
188 schema:givenName Nicholas
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014057560242.98
190 rdf:type schema:Person
191 sg:person.0615126743.56 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
192 schema:familyName Kim
193 schema:givenName Kevin
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615126743.56
195 rdf:type schema:Person
196 sg:person.0625610040.61 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
197 schema:familyName Noor
198 schema:givenName Rahat
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625610040.61
200 rdf:type schema:Person
201 sg:person.0702415721.17 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
202 schema:familyName Hwu
203 schema:givenName Patrick
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702415721.17
205 rdf:type schema:Person
206 sg:pub.10.1007/bf00434947 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006260699
207 https://doi.org/10.1007/bf00434947
208 rdf:type schema:CreativeWork
209 sg:pub.10.1007/s00520-003-0482-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038839491
210 https://doi.org/10.1007/s00520-003-0482-4
211 rdf:type schema:CreativeWork
212 sg:pub.10.2165/00003495-199754020-00008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009456971
213 https://doi.org/10.2165/00003495-199754020-00008
214 rdf:type schema:CreativeWork
215 sg:pub.10.2165/00003495-199855020-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030295362
216 https://doi.org/10.2165/00003495-199855020-00002
217 rdf:type schema:CreativeWork
218 https://app.dimensions.ai/details/publication/pub.1074487017 schema:CreativeWork
219 https://app.dimensions.ai/details/publication/pub.1077181555 schema:CreativeWork
220 https://doi.org/10.1002/cncr.11817 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010335838
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1002/ddr.430280111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037691728
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/0922-4106(90)90190-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041755679
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1080/07357900802027073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039879205
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1093/annonc/mdg417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047729604
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1093/annonc/mdh047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026990645
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1093/annonc/mdl137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023612379
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1093/annonc/mdp584 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007050927
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1093/ndt/9.10.1456 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082400333
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1093/oxfordjournals.annonc.a010762 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042885449
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1111/j.1476-5381.1995.tb13282.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1050303878
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.1998.16.5.1752 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083260950
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.1999.17.9.2971 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549933
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2000.18.1.158 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074572226
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2002.07.044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203018
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2006.06.0483 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017094741
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1517/14656566.1.2.207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030965593
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1634/theoncologist.4-3-191 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074487017
255 rdf:type schema:CreativeWork
256 https://doi.org/10.3109/07357900009038248 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033539371
257 rdf:type schema:CreativeWork
258 https://doi.org/10.3322/caac.20073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042069193
259 rdf:type schema:CreativeWork
260 https://doi.org/10.6004/jnccn.2009.0039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077902904
261 rdf:type schema:CreativeWork
262 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
263 schema:name Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA
264 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 430, 77030, Houston, TX, USA
265 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...